Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
NCT04418167 · JS InnoPharm, LLC · PHASE1 · suspended · last registry update 2025-09-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, JS InnoPharm, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BRAF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-01Results posted on the registry: National Cancer Institute (NCI), Dabrafenib Mesylate + Tazemetostat Hydrobromide (NCT04557956)
- 2026-08-26Results posted on the registry: Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2026-08-26Also stopped (terminated): Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2026-08-24Results posted on the registry: Melanoma Institute Australia, Dabrafenib + Trametinib (NCT02858921)
- 2026-07-28Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-M07D1 + Regorafenib (NCT07730489)
- 2026-07-23Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., IBI363 + bevacizumab + Investigator's choice of therapy (NCT07722494)
- 2026-07-22Results posted on the registry: Amgen, Sotorasib + Panitumumab (NCT05198934)
- 2026-07-20Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against BRAF (NCT07712848)
- 2026-07-20Results posted on the registry: Academic and Community Cancer Research United, Durvalumab + Regorafenib (NCT05194293)
- 2026-07-14Results posted on the registry: Jennerex Biotherapeutics, JX-594 + Sorafenib (NCT01171651)
- 2026-07-08Results posted on the registry: Jennerex Biotherapeutics, JX-594 recombinant vaccina GM-CSF (NCT01387555)
- 2026-07-06Results posted on the registry: Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-07-06Also stopped (terminated): Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-06-16Results posted on the registry: University of Southern California, Pembrolizumab + Regorafenib (NCT03657641)
- 2026-06-15Also stopped (withdrawn): University of Miami, Regorafenib (NCT06902246)
- 2026-06-12Also stopped (terminated): Northwestern University, Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab (NCT05576896)
- 2026-06-11Results posted on the registry: Pfizer, Encorafenib + Cetuximab (NCT04607421)
- 2026-06-10Results posted on the registry: Alliance for Clinical Trials in Oncology, Vemurafenib + Cobimetinib (NCT03224767)
- 2026-06-10Results posted on the registry: Australasian Gastro-Intestinal Trials Group, Regorafenib + Nivolumab (NCT04879368)
- 2026-06-04Also stopped (terminated): Pfizer, PF-07284892 + lorlatinib (NCT04800822)
- 2026-05-22Results posted on the registry: Novartis Pharmaceuticals, Dabrafenib + Trametinib (NCT04940052)
- 2026-05-19Results posted on the registry: National Cancer Institute (NCI), Dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide (NCT04439292)
- 2026-05-04Results posted on the registry: Mayo Clinic, Atezolizumab + Cobimetinib (NCT03554083)
- 2026-04-30Results posted on the registry: Pierre Fabre Medicament, Encorafenib + Cetuximab (NCT05004350)
- 2026-04-21Also stopped (withdrawn): SRH Wald-Klinikum Gera GmbH, Encorafenib & Binimetinib Treatment (NCT07092410)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision